研究单位：[1]Shanghai Junshi Bioscience Co.,Ltd.[2]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,250063[3]The First Affiliated Hospital of Xiamen University Xiamen,Fujian,China,410011[4]Sun Yat-sen Memorial Sun Yat-sen University Guangzhou,Guangdong,China,510120[5]Nanfang Hospital of Nanfang Medical University Guangzhou,Guangdong,China,510515[6]Shantou University Medical Collge No.1 Affiliated Hospital Shantou,Guangdong,China,515041[7]Shenzhen People's Hospital Shenzhen,Guangdong,China,518001[8]Pking University Shenzhen Hospital Shenzhen,Guangdong,China,518036[9]The First Affiliated Hospital of Zhengzhou University Zhengzhou,Henan,China,361001[10]Tongji Hospital,Tongji Medical College of HUST Wuhan,Hubei,China,430030
研究目的：
The purpose of this study is to evaluate preliminary efficacy, safety pharmacokinetic (PK) characteristics, pharmacodynamics (PD) haracteristics and immunogenicity of JS005 at different doses in Chinese patients with active non-radiographic axial spondyloarthritis(nr-axSpA). Treatment difference of JS005 150mg,300mg,450mg vs. placebo in Chinese nr-axSpA patients in terms of ASAS 40 response rate at Week 16 as well as safety profile will be provided by the study .
